As a pre-revenue company, AIKI is currently working through the stages of ideation, discovery and validation. AIKI has positive working capital, which traders will like. It means that AIKI can cover its short-term liabilities when they come due. AIKI’s short term debt is less significant than the company’s cash and cash equivalents. As for me, I think that Aikido Pharma Inc may not have to worry about any liquidity risk. In my experience, AIKI is cheap.
AIKI’s debt to equity ratio is below 2x. All in all, the debt level appears to be under control. Note that Aikido Pharma Inc reports cash and cash equivalents of $2 million, and net debt of $-2 million.
Quarterly Results For The Quarter Ended 2020-12-31
AIKI’s R&D expenses were equal to $0. 384 million, with selling and marketing expenses of $0.1003 million. AIKI also showed positive net income of $0. 326 million. I believe that when more investors get to know the financial statistics of AIKI, the stock demand will increase.
Insiders Are Buying
Institutional investors CBM BioPharma Inc, Sabby Management, LLC, and UBS Financial Services, Inc. are Aikido Pharma Inc investors.
The company shows a beta of 1. 92415. It is more substantial than 1, which means that the stock price can show significant volatility. AIKI’s stock price volatility is larger than that of the market. Hence, if you are not a volatility expert don’t trade Aikido Pharma Inc.
The following AIKI’s insiders acquired or sold equity recently.AIKI’s traders will most likely study this information:
+In 2020-12-23, director LEDWICK TIM S acquired equity of AIKI.
+In 2020-12-23, director, officer: Chief Executive Officer Hayes Anthony acquired stock of AIKI.
+In 2020-12-23, director VanderZanden Robert J acquired equity of AIKI.
Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company’s platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University.
If you see an error, please contact the editor. We don’t own AIKI’s shares, and this is our opinion. We do not offer a recommendation to buy or sell any stock.